ロード中...
What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?
In vitro and in vivo experimental data have pointed to new immunopathogenic mechanisms in primary Sjögren's syndrome (pSS). The availability of targeted treatment modalities has opened new ways to selectively target these mechanistic pathways in vivo. This has taught us that the role of proinfl...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3157640/ https://ncbi.nlm.nih.gov/pubmed/21371351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar3234 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|